Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community
Source: pixabay.com

Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community

The U.S. FDA just announced that it has accepted Genentech’s supplemental New Drug Application (sNDA) and has granted Priority Review for Zelboraf (vemurafenib) in patients with Erdheim-Chester disease from the…

Continue Reading Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community
This WM Patient from Across the Pond Has Been Reconnected With His Donor
Source: pixabay.com

This WM Patient from Across the Pond Has Been Reconnected With His Donor

Waldenstrom macroglobulinemia (WM) is a devastating form of non-Hodgkins lymphoma. Specifically, this cancer starts in the B cells of the body (B lymphocytes). Waldenstrom's cancer cells are capable of making…

Continue Reading This WM Patient from Across the Pond Has Been Reconnected With His Donor